We studied the kinetic properties of high-and low-molecular-mass forms of alkaline phosphatase purified from serum and bile, to clarify their interrelationships. They were found to share virtually identical kinetic properties, and to obey the same general kinetics as the liver-derived isoenzyme from serum and the low-molecular-mass isoenzyme from bile with regard to optimum conditions of assay, activation by magnesium ions, inhibition by L-homoarginine, inhibition by nickel and zinc ions, and inactivation by urea. Most of the characteristics such as Km (at low magnesium ion concentrations), K for L-homOargifline, and half-life for urea inactivation, were closely similar for lowand high-molecular-mass alkaline phosphatase. We conclude that these forms of alkaline phosphatase in plasma and bile are closely related. We discuss the possible nature of this relationship.
demonstrated that this ALP isoenzyme was specific for patients with liver disease and was most active in the sera of patients with cholestasis or hepatic metastases.
Recently, it was found to be a better discriminant than other commonly used liver-function tests in the diagnosis of metastases to the liver (3). In normal hepatic bile, nearly all the ALP is in the highmolecular-mass form (4). The appearance of a similar high-Mr ALP in serum from patients with liver disease therefore raises the question of whether these two forms are identical.
It also raises questions about the relationship between these forms and the low-molecular-mass isoenzymes in serum (particularly the liver-derived isoenzyme) and bile. Because no systematic studies on the kinetics of high-Mr ALP from serum and bile have been reported, comparative kinetic investigations on purifiedpreparationsare presented here.Our aim was to delineate similarities and differences between the high-and low-Mr forms obtained from serum and bile, as a preliminary step towards resolving the relationships, if any, between them.
Hitherto A molar absorptivity of 18 800 for p-nitrophenol was used in the calculations.
Purification
Step 1. Preparation of serum and bile. Human serum was dialyzed overnight at 4 #{176}C against 10 mmolfL Tris. HC1 buffer, pH 7.5. Normal hepatic bile was collected via a T-tube from patients, after cholecystectomy.
The bile was mixed with an equal volume of a 10 g/L solutionof protamine sulfate in water,to precipitatelipidand pigment (7).After centrifugation,the supernatant fluid, which was a clear, paleyellow,was concentrated 10-fold by negative-pressure ultrafiltration and dialyzed overnight at 4 #{176}C against 10 mmolfL Tris . HC1 buffer,pH 7.5.The dialyzedserum and bilewere designated "Purification Fraction I." Step 2. Ion-exchange chromatography. Purification Fraction I (5 mL) was applied to a DEAE-cellulose column (approximately 16 X 2.5 cm) pre-equilibratedwith the Tris buffer. After washing with one bed-volume of starting buffer, a salt gradient was set up, with 500 mL of startingbuffer in the mixing chamber and 500 mL of 0.5 mol/L NaC1 in the Tris buffer in the reservoir (flowrate:120 mL/h). The protein content of the eluate was monitored by its absorbance at 280 nm, and 5-mL fractions were collected. ALP activities in the fractions were measured by the test procedure described; ionic strengthswere measured with an LKB Conductolyzer, Type 5300B. The overallyieldof ALP from the column was about 90% . Figure 1 shows a typical elution profile for a serum containing liver-derived and high-Mr ALP. A similar profile was obtained forbileexcept that the second ALP peak was higher relative to the first peak. For both serum and bile, the second ALP peak, eluting at an ionic strength of 120-140 mmol/L, corresponded to high-Mr ALP (identified by Sepharose 6B chromatography and electrophoresis). The elution fractions corresponding to this peak were pooled and concentrated about 10-foldby negative-pressureultrafiltration. The concentrate was designated "Purification Fraction II." Step 3. Chromatography on Sepharose 6B. Purification Fraction II (2 mL) was applied to a 90 X 2.5 cm column of Sepharose 6B, pre-equilibratedwith 0.1 mol/L Tris. HC1 buffer,pH 7.7,containing 50 mmol of NaCl per litre. The column was eluted overnightat 4 #{176}C at a flow-rate of 28 mL/h. The protein content of the eluate was monitored by its absorbance at 280 nm, and 5-mL fractions were collected. Figure  2 shows a typical elution profile for Purification Fraction II from serum. The first peak, eluting in the void volume, corresponds to high-Mr ALP. The second peak, which corresponds to the isoenzyme of hepatic origin, was due to incomplete resolution of the peaks during the ion-exchange procedure. A similar elution profile was obtained for bile, but the void volume peak was higher relative to the low-Mr peak and the latter was broader.The totalyield of ALP from the column was 97%. Fractions corresponding to the void-volume peak were pooled and concentrated to give"PurificationFraction III." This was stored at -20 #{176}C and was used forthe kinetic experiments.
A similar purification schedule was followed for the partial purificationof ALP of liverand bone origin(identified by electrophoresis)from serum of patients with liveror bone disease, respectively, and for the low-Mr isoenzyme from bile.
These ALP isoenzymes elutedinthe first peak inpurification step 2 and in the second peak in purificationstep 3. For comparison, the kinetic studies were also performed on these ALP isoenzymes.
The ALP activities in each PurificationFraction were estimated by the test procedure described, and protein content was measured by the Lowry method (8). Typical purification schedules for liver, bone, and high-Mr ALP from serum are shown in Table 1 . Similar activities and yieldswere found for low-and high-Mr ALP from bile, but because of interference by some component in bilethe protein concentrationscould not be measured by eitherthe Lowry method (8) or the Coomassie Brilliant Blue method (9).
Statistical Analysis
We drew the linesin the Lineweaver-Burke plots, using estimates of Km and Vm obtained by a least-squares nonlinear fitting procedure of the measured (untransformed) velocityvs data points forthe substrate concentration (10). This procedure assumes equal variance of each of the measured data points. The fitted lines in the plots of reciprocal velocity vs inhibitor concentration were obtained by a weighted regressionprocedure in which equal variance was assumed for each velocityand which weighted the variance of each reciprocalvelocitydata point accordingly.The calculations and graphical output were programmed on a Hewlett-Packard 9821 Desk Calculator equipped with Printer/ Plotter.
One-way analysisof varianceon the fiveestimatesof K for each isoenzyme was performed according to the fixed-effects model in which K was regarded as a fixed but unknown quantity to be determined (11). We used the Scheff#{233} method to testfordifferencesbetween the mean K's foreach isoenzyme, because thismethod isappropriatewhen the difference has not been anticipated by the experimenter (11).
Results
Buffer Type, Concentration, and pH Optima
High-Mr ALP was compared with the liverisoenzyme in assessing the effect of three transphosphorylating buffers: diethanolamine, 2-amino-2-methylpropan-1-ol and Tris. borate. Like the liver isoenzyme, high-Mr ALP showed highest activityin diethanolamine and leastin Tris . borate. The optimal concentrations of the buffers were similar for both types of ALP (Figure 3 ), and the isoenzymes had similar pH optima (Figure 4) . The buffer described in our test procedure was selected as optimal, namely, diethanolamine buffer (1.5 mol/L, pH 10.2).
Km with Respect to Two Substrates
Using the standard test procedure, modified with respect to substrate concentration,we estimated the Km values of high-Mr ALP and the other isoenzymes from serum and bile, using p -nitrophenyl phosphate as substrate. We repeated the procedure, using a-naphthyl phosphate as substrate, except that forthissubstratethe reactionwas monitored by following the increasein absorbance at 340 nm. For both substrates, the Km of high-Mr ALP purifiedfrom serum was about twice the Km values of the other forms of ALP, including high-Mr ALP from bile (Table 2) .
Inhibition by L-Homoarginine
Preliminary investigation revealed that 4 mmol of L-phenylalanine per litre inhibited high-Mr ALP from serum and bileby only 4%, whereas 4 mmol/L L-homoarginine produced a 73% inhibition. We thereforestudied the latterinhibition in greater detail. Lineweaver-Burke plots at selected 
Activation by Magnesium Ions
We measured the activities of high-Mr and liverALP at various concentrations of added magnesium chloride.The endogenous magnesium ion concentration [Mg2+] in the buffered enzyme preparations,measured by atomic absorptionspectrophotometry, was found to be 8 smol/L forhigh-Mr ALP and 13 imol/L forthe liver-derived isoenzyme in serum. However, examination of the plotsof velocityvs total[Mg2) (endogenous plus exogenous) revealed a cleardisplacement of the data points along the [Mg2J axis. Itwas apparent that the fitwould be greatlyimproved by adjustment of the origin along thisaxis.On an empiricalbasis,we found that residual variance of the experimental points from the fitted curve was minimized by assuming an availableendogenous [MgO+J of 4 molfL forthe buffered high-Mr ALP and 2 imolfL forthe liverisoenzyme.
This procedure could be rationalizedby the hypothesis that not allthe endogenous Mg2+ was freeand availableto the enzyme: some might be inaccessiblybound to contaminating protein in the partly purified preparations. Some support forthishypothesis was provided by measure- with and without 0.5 mmol of magnesium chloride added per litre, in the fractions eluted after serum was applied to a column of Sepharose 6B. Although the totalendogenous [Mg2+] in the fractionsremained between 2 and 4 imol/L throughout the elution,the degree of activationby added Mg2+ was greaterinthe.presence of proteinin the eluate than in itsabsence. In other words, the degree of activation by added Mg2 paralleledthe protein elution profile (Figure 6 ).This implies that the endogenous protein was binding some of the endogenous Mg2+, resultingin a greateractivationby added Mg2. Figure 7 illustrates the effectof activationby Mg2 on high-Mr ALP, the concentrationsshown being the "best-fit" MgS+ concentrationsdescribed above. The concentration of Mg2 affectedVmax but had no significant effect on Km (Table  4) . Conversely, the concentration of substrate had no significant effect on KA, defined as the reciprocal of the negative intercept on the IMg2}1 axis inthe plotofreciprocal velocity (Table 5) .Ifitisassumed thatthe "best-fit" Mg2 concentrationrepresentedthe freeMg2+ available to activate the enzyme, the mean KA forhigh-Mr ALP (1.9zmol/L, SD 0.4 zmol/L) was significantly higher than that for the liver isoenzyme (1.1 mol/L, SD 0.2 zmolfL). However, it is not possible to draw firm conclusionsfrom these resultsbecause the assumptions underlying the derivationof theseestimates of KA could not be adequately tested. Table 6 shows the effects on ALP activity of certain divalent metal ions. Little inhibition was found at 1 tmol/L, but at 100 tmol/L high-Mr and liverALP were inhibitedmoderately by nickel ions and markedly by zinc ions.
Effect of Divalent Metal Ions Other than Magnesium

Inactivation by Urea
At urea concentrationsexceeding 3 mol/L, inhibitionby it isirreversible and time-dependent (12). After incubation of the ALP preparations with 5 mol/L urea, 50-oL samples were withdrawn at timed intervals, mixed immediately with 1 mL of diethanolamine bufferto diluteout the urea and prevent of both liver and high-Mr ALP followed similar mono-exponential decay curves up to 25 mm, with half-lives of 9.0mm and 7.0mm, respectively, as estimated graphically (Figure 8 ).
Discussion
Allisoenzymes were purified from serum or bile rather than from tissue sources because high-Me ALP inserum or bilemay not necessarilyoccur in the same form in the tissues. Furthermore, tissue extraction generally requires solubilization with butanol (13), which destroys or greatly alters the properties of high-Mr ALP (7, 14, 15) . Because the activity of ALP in serum and bile is low compared with that in liver or intestinal homogenates, and because large quantities of serum and bilewere not available, itwas not possibleto highly purify the preparations,nor was thisattempted. Instead,our aim was sufficiently to purify the isoenzymes that they could be separated from one another and from most of the contaminating plasma proteins,and allow kineticexperiments to be performed.
Kinetic experiments were performed on high-Me ALP purified from both serum and bile. Because it shows increased activityin serum only in patientswith liverdisease (2, 3, 14, 16) , it seems likely that it derives from the liver or bile. Its structureand propertiesmay thereforebe relatedto the liver isoenzyme in serum, or to the high-or low-Me biliaryisoenzymes, or to more than one of theseforms.These variousALP forms were purified and included in most of the kinetic experiments, for comparison. During activation of ALP by Mg2, it is thought that binding of substrateand Mg2 to the enzyme takes place as two independent events,and that Mg2 must thereforeplay a part in substratedecomposition (17). In kineticterms, this means that the Km value should not be affectedby the concentration of Mg2+ and, conversely, that KA (the dissociation constant of the enzyme_Mg2+ intermediate) should be unaffectedby the concentrationof substrate. We found thisto be true for both liver and high-Mr ALP, although the exact value of the KA value must remain in doubt, owing to the probable sequestrationof some endogenous Mg2+ by contaminating protein present in the assay mixture. At the concentrations of Mg2+ used in these activationstudies,the Km values of high-Mr and liverALP were similar,whereas a discrepancy arose at higher [Mg24. The explanation forthisobservation isuncertain but may be relatedto a possibleslightdegree of inhibition by the high [Mg2] (500 tmoVL) generally used in ALP measurements, which may affect the two ALP forms to differentextents.
L-Homoarginine
has been shown to act as an uncompetitive inhibitor of liver and bone ALP (18). Our study confirms this and demonstrates that the high-Mr ALP from serum and bile and also the low- The high-Mr ALP from serum differs from the 10W-Mr forms only with regard to Km at high Mg2j, whether p-nitrophenyl phosphate or cr-naphthyl phosphate is used as substrate; this difference was not observed for the high-Mr ALP from bile. Since high-Mr and liver ALP are therefore very similar in their kinetic properties, it seems unlikely that it will be possible to develop a simple routine method, based on kinetic properties or the action of inhibitors, for the assay of high-Mr ALP in serum.
Shinkai and Akedo (19) suggested that high-Mr ALP in serum may consist of membrane fragments released into the plasma of patients with liver disease. If this is so, one might further postulate that it may consist of liver ALP (which is membrane-bound within the liver) attached to the membrane moiety. Similarly, high-Mr ALP in bile may consist of low-Mr biliary ALP attached to membrane fragments. The almost identical kinetic properties we describe for high-and low-Mr forms of ALP purified from serum and bile are consistent with that hypothesis.The slight discrepancy
in Km values at high Mg2f]
does not contradict the theory, because a general characteristic of membrane-bound enzymes is a difference in kinetic parameters between membrane-bound and solubilized forms, although the fundamental mechanism of catalysis invariably remains identical (20). The phenomenon ("allotopy") arises from conformational changes between the two states. Work is currently in progress to explore further the nature of high-Mr ALP in serum and bile.
